XTX Topco Ltd Has $1.35 Million Stock Holdings in West Pharmaceutical Services, Inc. (NYSE:WST)

XTX Topco Ltd lowered its holdings in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 24.6% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 4,083 shares of the medical instruments supplier’s stock after selling 1,333 shares during the period. XTX Topco Ltd’s holdings in West Pharmaceutical Services were worth $1,345,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of the business. Fidelis Capital Partners LLC bought a new position in West Pharmaceutical Services in the 1st quarter valued at approximately $27,000. Crewe Advisors LLC grew its stake in shares of West Pharmaceutical Services by 322.7% during the second quarter. Crewe Advisors LLC now owns 93 shares of the medical instruments supplier’s stock worth $31,000 after buying an additional 71 shares during the last quarter. Quarry LP lifted its stake in shares of West Pharmaceutical Services by 155.3% in the 4th quarter. Quarry LP now owns 97 shares of the medical instruments supplier’s stock valued at $34,000 after acquiring an additional 59 shares during the last quarter. Hazlett Burt & Watson Inc. acquired a new stake in shares of West Pharmaceutical Services during the 1st quarter valued at $40,000. Finally, Northwest Investment Counselors LLC bought a new stake in West Pharmaceutical Services during the 1st quarter worth $40,000. Institutional investors and hedge funds own 93.90% of the company’s stock.

West Pharmaceutical Services Stock Performance

NYSE:WST opened at $308.15 on Friday. The stock’s 50-day moving average is $303.67 and its 200-day moving average is $337.77. The stock has a market cap of $22.45 billion, a P/E ratio of 40.65, a price-to-earnings-growth ratio of 10.58 and a beta of 1.01. West Pharmaceutical Services, Inc. has a 1-year low of $265.00 and a 1-year high of $413.70. The company has a current ratio of 2.34, a quick ratio of 1.68 and a debt-to-equity ratio of 0.03.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings results on Thursday, July 25th. The medical instruments supplier reported $1.52 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.74 by ($0.22). The business had revenue of $702.10 million during the quarter, compared to analyst estimates of $729.36 million. West Pharmaceutical Services had a net margin of 18.25% and a return on equity of 19.17%. The company’s revenue was down 6.9% compared to the same quarter last year. During the same quarter last year, the company posted $2.11 earnings per share. Equities research analysts anticipate that West Pharmaceutical Services, Inc. will post 6.42 earnings per share for the current year.

Insider Buying and Selling at West Pharmaceutical Services

In related news, VP Charles Witherspoon sold 1,029 shares of West Pharmaceutical Services stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $300.00, for a total value of $308,700.00. Following the transaction, the vice president now directly owns 1,478 shares of the company’s stock, valued at $443,400. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 0.53% of the company’s stock.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.